Cargando…
Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre
PURPOSE: To compare the efficacy of eye-drop interferon (IFN) α-2b 1 millionIU/mL with eye-ointment tacrolimus 0.03% in refractory vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: Fifty patients with VKC refractory to conventional treatment with topical corticosteroids and antihistamines af...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286782/ https://www.ncbi.nlm.nih.gov/pubmed/34285466 http://dx.doi.org/10.2147/OPTH.S322378 |
_version_ | 1783723782802767872 |
---|---|
author | Gupta, Sukriti Singh, Priyanka Singh, Mrityunjay Naik, Mayuresh Srivastava, Kartikeya |
author_facet | Gupta, Sukriti Singh, Priyanka Singh, Mrityunjay Naik, Mayuresh Srivastava, Kartikeya |
author_sort | Gupta, Sukriti |
collection | PubMed |
description | PURPOSE: To compare the efficacy of eye-drop interferon (IFN) α-2b 1 millionIU/mL with eye-ointment tacrolimus 0.03% in refractory vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: Fifty patients with VKC refractory to conventional treatment with topical corticosteroids and antihistamines after 4 weeks of regular use were selected retrospectively. Patients were divided into two groups depending on whether they received eye-ointment tacrolimus 0.03% three times a day or eye-drop IFN alpha-2b 1 millionIU/mL three times a day and were followed up for 24 months. The main outcome measures were total subjective symptom score (TSSS) and total objective ocular score (TOSS). RESULTS: Mean baseline TSSS was 7.24±1.98 in Group A (tacrolimus group) and 7.84±1.82 in Group B (IFN group), and it reduced to 1.12±0.83 in Group A and 0.62±0.41 in Group B at 6 months, which was statistically significant compared to the baseline score (p<0.05) as well as between the two groups. Mean baseline TOSS was 6.72±2.07 in Group A and 6.56±2.04 in Group B, and it improved to 1 month onwards to 1.52±0.87 in Group A and 1.0±0.71 in Group B at 6 months, which was statistically significant compared to the baseline score (p<0.05) as well as between the two groups. Side effects like stinging and burning sensations were seen in the tacrolimus group only. CONCLUSION: Our study suggests that while both eye-drop IFN α-2b 1 millionIU/mL and eye-ointment tacrolimus eye ointment 0.03% are both safe and effective steroid-sparing agents in steroid-resistant VKC. IFN α-2b results in greater improvement in subjective symptoms and objective signs, has fewer side effects in long term and is better tolerated as compared to tacrolimus. |
format | Online Article Text |
id | pubmed-8286782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82867822021-07-19 Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre Gupta, Sukriti Singh, Priyanka Singh, Mrityunjay Naik, Mayuresh Srivastava, Kartikeya Clin Ophthalmol Original Research PURPOSE: To compare the efficacy of eye-drop interferon (IFN) α-2b 1 millionIU/mL with eye-ointment tacrolimus 0.03% in refractory vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: Fifty patients with VKC refractory to conventional treatment with topical corticosteroids and antihistamines after 4 weeks of regular use were selected retrospectively. Patients were divided into two groups depending on whether they received eye-ointment tacrolimus 0.03% three times a day or eye-drop IFN alpha-2b 1 millionIU/mL three times a day and were followed up for 24 months. The main outcome measures were total subjective symptom score (TSSS) and total objective ocular score (TOSS). RESULTS: Mean baseline TSSS was 7.24±1.98 in Group A (tacrolimus group) and 7.84±1.82 in Group B (IFN group), and it reduced to 1.12±0.83 in Group A and 0.62±0.41 in Group B at 6 months, which was statistically significant compared to the baseline score (p<0.05) as well as between the two groups. Mean baseline TOSS was 6.72±2.07 in Group A and 6.56±2.04 in Group B, and it improved to 1 month onwards to 1.52±0.87 in Group A and 1.0±0.71 in Group B at 6 months, which was statistically significant compared to the baseline score (p<0.05) as well as between the two groups. Side effects like stinging and burning sensations were seen in the tacrolimus group only. CONCLUSION: Our study suggests that while both eye-drop IFN α-2b 1 millionIU/mL and eye-ointment tacrolimus eye ointment 0.03% are both safe and effective steroid-sparing agents in steroid-resistant VKC. IFN α-2b results in greater improvement in subjective symptoms and objective signs, has fewer side effects in long term and is better tolerated as compared to tacrolimus. Dove 2021-07-14 /pmc/articles/PMC8286782/ /pubmed/34285466 http://dx.doi.org/10.2147/OPTH.S322378 Text en © 2021 Gupta et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Gupta, Sukriti Singh, Priyanka Singh, Mrityunjay Naik, Mayuresh Srivastava, Kartikeya Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
title | Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
title_full | Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
title_fullStr | Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
title_full_unstemmed | Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
title_short | Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre |
title_sort | is interferon α-2b 1 millioniu/ml truly better than tacrolimus 0.03% for steroid-resistant vkc ?: our 2-year experience at a tertiary health-care centre |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286782/ https://www.ncbi.nlm.nih.gov/pubmed/34285466 http://dx.doi.org/10.2147/OPTH.S322378 |
work_keys_str_mv | AT guptasukriti isinterferona2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT singhpriyanka isinterferona2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT singhmrityunjay isinterferona2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT naikmayuresh isinterferona2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre AT srivastavakartikeya isinterferona2b1millioniumltrulybetterthantacrolimus003forsteroidresistantvkcour2yearexperienceatatertiaryhealthcarecentre |